ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting

Core Insights - Oryzon Genomics S.A. held an Extraordinary General Shareholders' Meeting where 33,581,589 voting rights were represented, accounting for 37.7938% of the share capital [1][6]. Resolutions Approved - All resolutions proposed by the Board of Directors received favorable votes ranging from 93% to 98% [2]. - Key resolutions included amendments to the Company's Bylaws, approval of a new Remuneration Policy for directors, and a Long-Term Incentive Plan for executives [7]. Financial and Corporate Actions - A capital increase of up to €125 million was approved, with the exclusion of preemptive subscription rights [7]. - The Company is focused on personalized medicine in CNS disorders and oncology/hematology, with a clinical portfolio that includes two LSD1 inhibitors [4].